28. Systemic amyloidosis
212 clinical trials,   234 drugs   (DrugBank: 72 drugs),   54 drug target genes,   170 drug target pathways

Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00807872
(ClinicalTrials.gov)
December 200811/12/2008Radioimmunoimaging of AL AmyloidosisRadioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4Primary AmyloidosisBiological: 124I-labeled monoclonal antibody Mu 11-1F4University of TennesseeFDA Office of Orphan Products DevelopmentCompleted21 Years90 YearsBoth40Phase 1United States
2NCT01409148
(ClinicalTrials.gov)
November 200828/7/2011Radioimmunoimaging of AL AmyloidosisRadioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4AL AmyloidosisBiological: 124I-labeled monoclonal antibody Mu 11-1F4University of TennesseeFood and Drug Administration (FDA)Completed21 Years90 YearsBoth38Phase 1United States